|
1
|
Robetson RP, Harmon J, Tran PO, Tanaka Y
and Takahashi H: Glucose toxicity in beta-cells: type 2 diabetes,
good radicals gone bad, and the glutathi-one connection. Diabetes.
52:581–587. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cobitz AR and Ambery P: Medical management
of hyperglycemia in type 2 type diabetes: a consensus algorithm for
the initiation and adjustment of therapy: a consensus statement of
the American Diabetes Association and the European Association for
the Study of Diabetes. Response to Nathan et al. Diabetes Care.
32:e582009. View Article : Google Scholar
|
|
3
|
Swinnen SG, Dain MP, Aronson R, et al: A
24-week, randomized, treat-to-target trial comparing initiation of
insulin glargine once-daily with insulin detemir twice-daily in
patients with type 2 diabetes inadequately controlled on oral
glucose-lowering drugs. Diabetes Care. 33:1176–1178. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Riddle MC, Rosenstock J and Gerich J:
Insulin Glargine 4002 Study Investigators: The treat-to-target
trial: Randomized addition of glargine or human NPH insulin to oral
therapy of type 2 diabetic patients. Diabetes Care. 26:3080–3086.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Janka HU, Plewe G, Riddle MC, et al:
Comparison of basal insulin added to oral agents versus twice-daily
premixed insulin as initial insulin therapy for type 2 diabetes.
Diabetes Care. 28:254–259. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yki-Jarvinen H, Kauppinen-Makelin R,
Tiikkainen M, et al: Insulin glargine or NPH combined with
metformin in type 2 diabetes: The LANMET study. Diabetologia.
49:442–451. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lepore M, Pampanelli S, Fanelli C, et al:
Pharmacokinetics and pharmacodynamics of subcutaneous injection of
long-acting human insulin analog glargine, NPH insulin, and
ultralente human insulin and continuous subcutaneous infusion of
insulin lispro. Diabetes. 49:2142–2148. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stentz FB, Umpierrez GE, Cuervo R and
Kitabchi AE: Proinflammatory cyto-kines, markers of cardiovascular
risks, oxidative stress, and lip id peroxidetion in patients with
hyperglycemic crises. Diabetes. 53:2079–2086. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Forouhi NG, Sattar N and McKeigue PM:
Relation of C-reactive protein to body fat distribution and
features of the metabolic syndrome in Europeans and South Asians.
Int J Obes Relat Metab Disord. 25:1327–1331. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nayak BS, Ramsingh D, Gooding S, et al:
Plasma adiponectin levels are related to obesity, inflammation,
blood lipids and insulin in type 2 diabetic and non-diabetic
Trinidadians. Prim Care Diabetes. 4:187–192. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Winkler C and Cseh K: Molecular mechanisms
and correlations of insulin resistance, obesity, and type 2
diabetes mellitus. Orv Hetil. 150:7717802009.(In Hungarian).
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Inoue M, Maehata E, Yano M, Taniyama M and
Suzuki S: Correlation between the adiponectin-leptin ratio and
parameters of insulin resistance in patients with type 2 diabetes.
Metabolism. 54:281–286. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lindsav RS, Funabashi T, Hanson RL, et al:
Adiponectin and development of type 2 diabetes in the Pima Indian
population. Lancet. 360:57–58. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kubota N, Terauchi Y, Yamauchi T, et al:
Disruption of adiponectin causes insulin resistance and neointimal
formation. J Biol Chem. 277:25863–25866. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stefan N, Stumvoll M, Vozarova B, et al:
Plasma adiponectin and endogenous glucose production in humans.
Diabetes Care. 26:3315–3319. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hivert MF, Sullivan LM, Shrader P, et al:
Insulin resistance influences the association of adiponectin levels
with diabetes incidence in two population-based cohorts: the
Cooperative Health research in the Region of Augsburg (KORA) S4/F4
study and the Framingham Offspring Study. Diabetologia.
54:1019–1024. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lau CH and Muniandy S: Adiponectin and
resistin gene polymorphisms in association with their respective
adipokine levels. Ann Hum Genet. 75:370–382. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chu CH, Lam HC, Lee JK, et al:
Hyperthyroidism-associated insulin resistance is not mediated by
adiponectin levels. J Thyroid Res. 2011:1947212011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wolf AM, Wolf D, Rumpold H, Enrich B and
Tilg H: Adiponectin induces the anti-inflammatory cytokines IL-10
and IL-1RA in human leukocytes. Biochem Biophys Res Commun.
323:630–635. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Imai S: Nicotinamide
phosphoribosyltansferase (Nampt): a link between NAD biology,
metabolism, and diseases. Curr Pharm Des. 15:20–28. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin Y, Berg AH, Iyengar P, et al: The
hyperglycemia-induced inflammatory response in adipocytes: the role
of reactive oxygen species. J Biol Chem. 280:4617–4626. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang W, Lu J, Weng J, et al: Prevalence of
diabetes among men and women in China. N Engl J Med. 362:1090–1101.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen MP, Chung FM, Chang DM, et al:
Elevated plasma level of vifatin/pre-B cell colony-enhancing factor
in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab.
91:295–299. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jalovaara K, Santaniemi M, Timonen M, et
al: Low serum adiponectin level as a predictor of impaired glucose
regulation and type 2 diabetes mellitus in a middle-aged Finnish
population. Metabolism. 57:1130–1134. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Su SC, Pei D, Hsieh CH, et al: Circulating
pro-inflammatory cytokines and adiponectin in young men with type 2
diabetes. Acta Diabetol. 48:113–119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wong WT, Tian XY, Xu A, et al: Adiponectin
is required for PPAR൞-mediated improvement of endothelial function
in diabetic mice. Cell Metab. 14:104–105. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Choudhary S, Sinha S, Zhao Y, et al:
NF-kappaB-inducing kinase (NIK) mediates skeletal muscle insulin
resistance: blockade by adiponectin. Endocrinology. 152:3622–3627.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Skrabal CA, Czaja J, Honz K, et al:
Adiponectin - its potential to predict and prevent coronary artery
disease. Thorac Cardiovasc Surg. 59:201–206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kyriazi E, Tsiotra PC, Boutati E, et al:
Effects of adiponectin in TNF-α, IL-6, IL-10 cytokine production
from coronary artery disease macrophages. Horm Metab Res.
43:537–544. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tesauro M, Rizza S, Iantorno M, et al:
Vascular, metabolic, and inflammatory abnormalities in
normoglycemic offspring of patients with type 2 diabetes mellitus.
Metabolism. 56:413–419. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pickup JC: Inflammation and activated
innate immunity in the pathogenesis of type 2 diabetes. Diabetes
Care. 27:813–823. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Donath MY and Shoelson SE: Type 2 diabetes
as an inflammatory disease. Nat Rev Immunol. 11:98–107. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cai XJ, Chen L, Li L, et al: Adiponectin
inhibits lipopolysaccharide-induced adventitial fibroblast
migration and transition to myofibroblasts via AdipoR1-AMPK-iNOS
pathway. Mol Endocrinol. 24:218–228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fagerberg B, Kellis D, Bergstrom G and
Behre CJ: Adiponectin in relation to insulin sensitivity and
insulin secretion in the development of type 2 diabetes: a
prospective study in 64-year-old women. J Intern Med. 269:636–643.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ran J, Xiong X, Liu W, et al: Increased
plasma adiponectin closely associates with vascular endothelial
dysfunction in type 2 diabetic patients with diabetic nephropathy.
Diabetes Res Clin Pract. 88:177–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Curat CA, Wegner V, Sengenes C, et al:
Macrophages in human visceral adipose tissue: increased
accumulation in obesity and a source of resistin and visfatin.
Diabetologia. 49:744–747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dahl TB, Yndestad A, Skjelland M, et al:
Increased expression of visfatin in macrophages of human unstable
carotid and coronary atherosclerosis: possible role in inflammation
and plaque destabilization. Circulation. 115:972–980. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Adya R, Tan BK, Chen J and Randeva HS:
Nuclear factor-kappaB induction by visfatin in human vascular
endothelial ceils: its role in MMP-2/9 production and activation.
Diabetes Care. 31:758–760. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim SR, Jung YH, Park HJ, et al:
Upregulation of thromboxane synthase mediates visfatin-induced
interleukin-8 expression and angiogenic activity in endothelial
cells. Biochem Biophys Res Commun. 418:662–668. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kadoglou NP, Sailer N, Moumtzouoglou A, et
al: Visfatin (nampt) and ghrelin as novel markers of carotid
atherosclerosis in patients with type 2 diabetes. Exp Clin
Endocrinol Diabetes. 118:75–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sethi JK and Vidal-Puig A: Visfatin: the
missing link between intra-abdominal obesity and diabetes? Trends
Mol Med. 11:344–347. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Samal B, Sun Y, Stearns G, Xie C, Suggs S
and McNiece I: Cloning and characterization of the cDNA encoding a
novel human pre-B-cell colony-enhancing factor. Mol Cell Biol.
14:1431–1437. 1994.PubMed/NCBI
|
|
43
|
Hug C and Lodish HF: Medicine. Visfatin: a
new adipokine. Science. 307:366–367. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Retnakaran R, Youn BS, Liu Y, et al:
Correlation of circulating full-length visfatin (PBEF/NAMPT) with
metabolic parameters in subjects with and without diabetes: a
cross-sectional study. Clin Endocrinol (Oxf). 69:885–893. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Holman RR, Paul SK, Bethel MA, Matthews DR
and Neil HA: 10-year follow-up of intensive glucose control in 2
type diabetes. N Engl J Med. 359:1577–1589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Forst T, Larbig M, Hobberg C, et al:
Adding insulin glargine vs. NPH insulin to metformin results in a
more efficient postprandial beta-cell protection in individuals
with type 2 diabetes. Diabetes Obes Metab. 12:437–441. 2010.
View Article : Google Scholar : PubMed/NCBI
|
